Cheng CH, Hao WR, Cheng TH. Selenoprotein P1 as a biomarker of insulin resistance in pediatric obesity: Insights and implications. World J Clin Pediatr 2025; 14(1): 99652 [DOI: 10.5409/wjcp.v14.i1.99652]
Corresponding Author of This Article
Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw
Research Domain of This Article
Multidisciplinary Sciences
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Pediatr. Mar 9, 2025; 14(1): 99652 Published online Mar 9, 2025. doi: 10.5409/wjcp.v14.i1.99652
Selenoprotein P1 as a biomarker of insulin resistance in pediatric obesity: Insights and implications
Chun-Han Cheng, Wen-Rui Hao, Tzu-Hurng Cheng
Chun-Han Cheng, Department of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei 23561, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11002, Taiwan
Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan
Co-first authors: Chun-Han Cheng and Wen-Rui Hao.
Author contributions: The authors, Cheng CH, Hao WR, and Cheng TH, have contributed to this editorial, with Cheng CH and Hao WR primarily responsible for writing, and Cheng TH overseeing revisions. All authors have read and approved the final manuscript.
Conflict-of-interest statement: All authors declare having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw
Received: July 26, 2024 Revised: October 31, 2024 Accepted: November 12, 2024 Published online: March 9, 2025 Processing time: 146 Days and 9 Hours
Abstract
This editorial discusses the findings of Elbarky et al on the role of selenoprotein P1 (SEPP1) in pediatric obesity and insulin resistance. Their study uncovered significantly lower SEPP1 Levels in children who were obese compared with healthy peers, demonstrating a negative correlation between SEPP1 levels and measures of adiposity and insulin resistance. These findings suggest that SEPP1 is a biomarker useful in the early identification of insulin resistance in pediatric populations. This editorial emphasizes the clinical implications of the study and calls for further research to validate and explore the role of SEPP1 in metabolic health.
Core Tip: This editorial discusses the findings of Elbarky et al that selenoprotein P1 (SEPP1) is a potential biomarker of insulin resistance in children with obesity. Their study suggests that lower SEPP1 levels are correlated with increased adiposity and insulin resistance, emphasizing the potential of SEPP1 to inform early detection and intervention strategies for pediatric metabolic disorders. Further research is necessary to validate these findings and explore the clinical applications of SEPP1.
